These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34581402)

  • 21. Evidence for a 10-year TBE vaccine booster interval: an evaluation of current data.
    Schelling J; Einmahl S; Torgler R; Larsen CS
    Expert Rev Vaccines; 2024; 23(1):226-236. PubMed ID: 38288983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity and Sex Affect the Immune Responses to Tick-Borne Encephalitis Booster Vaccination.
    Garner-Spitzer E; Poellabauer EM; Wagner A; Guzek A; Zwazl I; Seidl-Friedrich C; Binder CJ; Stiasny K; Kundi M; Wiedermann U
    Front Immunol; 2020; 11():860. PubMed ID: 32528467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response to tick-borne encephalitis (TBE) booster vaccination after prolonged time intervals to primary immunization with the rapid schedule.
    Schöndorf I; Schönfeld C; Nicolay U; Zent O; Banzhoff A
    Int J Med Microbiol; 2006 May; 296 Suppl 40():208-12. PubMed ID: 16531118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis.
    Domnich A; Panatto D; Arbuzova EK; Signori A; Avio U; Gasparini R; Amicizia D
    Hum Vaccin Immunother; 2014; 10(10):2819-33. PubMed ID: 25483679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence of protective immunity following vaccination against tick-borne encephalitis--longer than expected?
    Rendi-Wagner P; Kundi M; Zent O; Dvorak G; Jaehnig P; Holzmann H; Mikolasek A; Kollaritsch H
    Vaccine; 2004 Jul; 22(21-22):2743-9. PubMed ID: 15246606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination rate and adherence of tick-borne encephalitis vaccination in Germany.
    Schley K; Malerczyk C; Beier D; Schiffner-Rohe J; von Eiff C; Häckl D; Süß J
    Vaccine; 2021 Jan; 39(5):830-838. PubMed ID: 33414049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5mL in adults.
    Konior R; Brzostek J; Poellabauer EM; Jiang Q; Harper L; Erber W
    Vaccine; 2017 Jun; 35(28):3607-3613. PubMed ID: 28545923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of delayed TBE-vaccine booster.
    Askling HH; Vene S; Rombo L; Lindquist L
    Vaccine; 2012 Jan; 30(3):499-502. PubMed ID: 22122857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of delayed TBE-vaccine booster after primary vaccination.
    Aerssens A; Cochez C; Niedrig M; Heyman P; Kühlmann-Rabens I; Soentjens P
    J Travel Med; 2016 Feb; 23(2):tav020. PubMed ID: 26858269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up.
    Rendi-Wagner P; Paulke-Korinek M; Kundi M; Wiedermann U; Laaber B; Kollaritsch H
    Vaccine; 2007 Jun; 25(27):5097-101. PubMed ID: 17555850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of the tick-borne encephalitis vaccination (2009-2019): A systematic review.
    Rampa JE; Askling HH; Lang P; Zens KD; Gültekin N; Stanga Z; Schlagenhauf P
    Travel Med Infect Dis; 2020; 37():101876. PubMed ID: 32931931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Suspected neurological side-effects of tick-borne meningoencephalitis vaccination: experiences of the Swiss Adverse Drug Reaction Reporting Center].
    Doser AK; Hartmann K; Fleisch F; Kuhn M
    Praxis (Bern 1994); 2002 Jan; 91(5):159-62. PubMed ID: 11865774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Self-reported tick-borne encephalitis (TBE) vaccination coverage in Europe: Results from a cross-sectional study.
    Erber W; Schmitt HJ
    Ticks Tick Borne Dis; 2018 May; 9(4):768-777. PubMed ID: 29501619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allergic patients with and without allergen-specific immunotherapy mount protective immune responses to tick-borne encephalitis vaccination in absence of enhanced side effects or propagation of their Th2 bias.
    Garner-Spitzer E; Seidl-Friedrich C; Zwazl I; Hofer M; Kinaciyan T; Jarisch R; Stiasny K; Zlabinger GJ; Kundi M; Wiedermann U
    Vaccine; 2018 May; 36(20):2816-2824. PubMed ID: 29673942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology of tick-borne encephalitis (TBE) in international travellers to Western/Central Europe and conclusions on vaccination recommendations.
    Steffen R
    J Travel Med; 2016 Apr; 23(4):. PubMed ID: 27087558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Field effectiveness of vaccination against tick-borne encephalitis.
    Heinz FX; Holzmann H; Essl A; Kundi M
    Vaccine; 2007 Oct; 25(43):7559-67. PubMed ID: 17869389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation of preventive measures against tick-borne infections in a non-endemic area for tick-borne encephalitis-Results from a population-based survey in Lower Saxony, Germany.
    Caputo M; Stumpe V; Rübsamen N; Mikolajczyk RT; Karch A
    Ticks Tick Borne Dis; 2019 Apr; 10(3):614-620. PubMed ID: 30797728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparable immune responsiveness but increased reactogenicity after subcutaneous versus intramuscular administration of tick borne encephalitis (TBE) vaccine.
    Hopf S; Garner-Spitzer E; Hofer M; Kundi M; Wiedermann U
    Vaccine; 2016 Apr; 34(17):2027-34. PubMed ID: 26768126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tick-borne encephalitis after vaccination: vaccine failure or misdiagnosis.
    Grgič-Vitek M; Avšič-Županc T; Klavs I
    Vaccine; 2010 Oct; 28(46):7396-400. PubMed ID: 20854899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seropersistence and booster response following vaccination with FSME-IMMUN in children, adolescents, and young adults.
    Poellabauer E; Angermayr R; Behre U; Zhang P; Harper L; Schmitt HJ; Erber W
    Vaccine; 2019 May; 37(24):3241-3250. PubMed ID: 30928173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.